Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Biotech
BMS-J&J blood thinner fails phase 3, denting blockbuster hopes
The partners stopped the phase 3 early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.
Nick Paul Taylor
Nov 14, 2025 8:10am
BMS boosts cancer trials with Sarah Cannon's platform
Nov 12, 2025 12:30pm
Pfizer lays out its PD-1xVEGF bispecific research strategy
Nov 11, 2025 11:43am
BMS removes 2 clinical programs from pipeline
Oct 30, 2025 1:14pm
ESMO: BMS believes ADC data allow it to 'stay ahead' of rivals
Oct 17, 2025 10:30am
BMS inks $1.5B deal to pull Orbital into its sphere of influence
Oct 10, 2025 8:45am
